74962 Federal Register / Vol. 89, No. 178 / Friday, September 13, 2024 / Notices 

living with HIV (PLHIV). Funding 

amounts for years 2–5 will be set at 

continuation. 

DATES: The period for this award will be 

January 1, 2025, through September 29, 

2029. 

FOR FURTHER INFORMATION CONTACT: 

Vance Brown, Global Health Center, 

Centers for Disease Control and 

Prevention, 351 Independence Avenue, 

P.O Box 320065, Lusaka, Zambia, 

Telephone: +260–761–428–720, email: 

vhu7@cdc.gov. 

SUPPLEMENTARY INFORMATION: The sole 

source award will support the Zambian 

Ministry of Health (MOH) to achieve 

and sustain HIV epidemic control gains 

by providing programmatic oversight, 

coordination, and direct service delivery 

in the provision of comprehensive HIV/ 

TB prevention, treatment, and support 

services, while strengthening health 

systems for sustainability. 

NWPHO is the only entity that can 

carry out this work, as it is the sole 

government institution with the 

mandate to support the health service 

delivery through capacity building, 

systems strengthening and oversight for 

HIV program implementation for the 

population of the Northwestern 

Province (NWP) of Zambia by the 

National Public Health Act of Zambia. 

NWPHO has been actively 

implementing PEPFAR programs 

through support provided by USGawarded implementing partners funded 

by USAID. The government-togovernment award is only possible to be 

executed with NWPHO as the registered 

sub-national provincial health authority 

in NWP Zambia. 

Summary of the Award 

Recipient: Northwestern Provincial 

Health Office (NWPHO). 

Purpose of the Award: The purpose of 

this award is to provide NWPHO with 

CDC Technical Assistance and financial 

support to maintain and sustain the 

province’s overall oversight and quality 

assurance for the implementation of 

high-impact HIV combination 

prevention, treatment, and support 

services, including clinical, 

surveillance, and laboratory services as 

well as to identify and mitigate 

emerging disease threats for PLHIV. The 

award aims to strengthen capacity 

development activities, while providing 

optimal health systems strengthening in 

support of continued and sustainable 

HIV epidemic control in Zambia. 

Amount of Award: The approximate 

year 1 funding amount will be 

$4,450,000 in Federal Fiscal Year (FYY) 

2025 funds, subject to the availability of 

funds. Funding amounts for years 2–5 

will be set at continuation. 

Authority: This program is authorized 

under Public Law 108–25 (the United 

States Leadership Against HIV AIDS, 

Tuberculosis and Malaria Act of 2003) 

[22 U.S.C. 7601, et seq.] and Public Law 

110–293 (the Tom Lantos and Henry J. 

Hyde United States Global Leadership 

Against HIV/AIDS, Tuberculosis, and 

Malaria Reauthorization Act of 2008), 

and Public Law 113–56 (PEPFAR 

Stewardship and Oversight Act of 2013). 

Period of Performance: January 1, 

2025, through September 29, 2029. 

Dated: September 4, 2024. 

Terrance Perry, 

Acting Director, Office of Grants Services, 

Centers for Disease Control and Prevention. 

[FR Doc. 2024–20790 Filed 9–12–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–1822–N] 

Medicare Program; Town Hall Meeting 

on the Fiscal Year 2026 Applications 

for New Medical Services and 

Technologies Add-On Payments 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), Department 

of Health and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: This notice announces a town 

hall meeting in accordance with the 

Social Security Act (the Act) to discuss 

fiscal year (FY) 2026 applications for 

add-on payments for new medical 

services and technologies under the 

hospital inpatient prospective payment 

system (IPPS). Interested parties are 

invited to this virtual meeting to present 

their comments, recommendations, and 

data regarding whether the FY 2026 new 

medical services and technologies 

applications meet the substantial 

clinical improvement criterion. 

DATES: 

Meeting Dates: The New Technology 

Town Hall meeting announced in this 

notice will be held virtually on 

Wednesday, December 11, 2024, and 

Thursday, December 12, 2024 (the 

number of presentations will determine 

if a second day for the meeting is 

necessary; see the SUPPLEMENTARY

INFORMATION section for details 

regarding the second day of the meeting 

and the posting of the final schedule). 

The New Technology Town Hall 

meeting will begin each day at 9 a.m. 

eastern standard time (EST) and checkin via online platform will begin at 8:30 

a.m. EST. 

Deadline for Registration of Presenters 

at the New Technology Town Hall 

Meeting: The deadline to register to 

present at the New Technology Town 

Hall meeting is 5 p.m., EST on Monday, 

November 4, 2024. 

Deadline for Submission of Agenda 

Item(s) or Written Comments for the 

New Technology Town Hall Meeting: 

Written comments and agenda items 

(public comments to be delivered at the 

New Technology Town Hall meeting) 

for discussion at the New Technology 

Town Hall meeting, including agenda 

items by presenters (presentation slide 

decks), must be received by 5 p.m. EST 

on Tuesday, November 12, 2024. 

Deadline for Requesting Special 

Accommodations: The deadline to 

submit requests for special 

accommodations is 5 p.m., EST on 

Tuesday, November 12, 2024. 

Deadline for Submission of Written 

Comments after the New Technology 

Town Hall Meeting for Consideration in 

the Fiscal Year (FY) 2026 Hospital 

Inpatient Prospective Payment System/ 

Long Term Care PPS (IPPS/LTCH PPS) 

Proposed Rule: Individuals may submit 

written comments after the New 

Technology Town Hall meeting, as 

specified in the ADDRESSES section of 

this notice, on whether the service or 

technology represents a substantial 

clinical improvement. These comments 

must be received by 5 p.m. EST on 

Monday, December 16, 2024, to ensure 

consideration in the FY 2026 IPPS/ 

LTCH PPS proposed rule. 

ADDRESSES: 

Meeting Location: The New 

Technology Town Hall meeting will be 

held virtually via live stream technology 

or webinar and listen-only via toll-free 

teleconference. Live stream or webinar 

and teleconference dial-in information 

will be provided through an upcoming 

listserv/email notice and will appear on 

the final meeting agenda, which will be 

posted on the New Technology website 

when available at: http://www.cms.gov/ 

Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/ 

newtech.html. Continue to check the 

website for updates. 

Registration and Special 

Accommodations: Individuals wishing 

to present at the meeting must follow 

the instructions located in section III. of 

this notice. Individuals who need 

special accommodations should send an 

email to newtech@cms.hhs.gov. 

Submission of Agenda Item(s) or 

Written Comments for the New 

Technology Town Hall Meeting: Each 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 178 / Friday, September 13, 2024 / Notices 74963 

presenter must submit at least one 

agenda item for presentation regarding 

whether a FY 2026 application meets 

the substantial clinical improvement 

criterion. Other items such as written 

comments, questions or other 

statements must not exceed three singlespaced typed pages and may be sent via 

email to newtech@cms.hhs.gov. 

FOR FURTHER INFORMATION CONTACT: 

Drew Kasper, (410) 786–8926, 

drew.kasper@cms.hhs.gov and 

newtech@cms.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background on the Add-On Payments 

for New Medical Services and 

Technologies Under the IPPS 

Effective for discharges beginning on 

or after October 1, 2001, section 

1886(d)(5)(K)(i) of the Act requires the 

Secretary to establish (after notice and 

opportunity for public comment) a 

mechanism to recognize the costs of 

new services and technologies under the 

hospital inpatient prospective payment 

system (IPPS). In addition, section 

1886(d)(5)(K)(vi) of the Act specifies 

that a medical service or technology will 

be considered ‘‘new’’ if it meets criteria 

established by the Secretary (after notice 

and opportunity for public comment). 

For further discussion on the new 

technology add-on payment criteria, we 

refer readers to the new technology addon payment final rule (66 FR 46912, 

September 7, 2001), as well as the FY 

2012 IPPS/LTCH PPS final rule (76 FR 

51572 through 51574), the FY 2020 

IPPS/LTCH PPS final rule (84 FR 42288 

through 42300), and the FY 2021 IPPS/ 

LTCH PPS final rule (85 FR 58736 

through 58742). 

As finalized in the FY 2020 and FY 

2021 IPPS/LTCH PPS final rules, 

technologies which are eligible for the 

alternative new technology pathway for 

transformative new devices or the 

alternative new technology pathway for 

certain antimicrobials do not need to 

meet the requirement under 42 CFR 

412.87(b)(1) that the technology 

represent an advance that substantially 

improves, relative to technologies 

previously available, the diagnosis or 

treatment of Medicare beneficiaries. 

These medical devices or products will 

also be considered not substantially 

similar to an existing technology for 

purposes of new technology add-on 

payment under the IPPS. See the FY 

2020 IPPS/LTCH PPS final rule (84 FR 

42292 through 42297) and the FY 2021 

IPPS/LTCH PPS final rule (85 FR 58737 

through 58739) for additional 

information. 

In the FY 2020 IPPS/LTCH PPS final 

rule (84 FR 42289 through 42292), we 

codified in our regulations at § 412.87 

the following aspects of how we 

evaluate substantial clinical 

improvement for purposes of new 

technology add-on payments under the 

IPPS to determine if a new technology 

meets the substantial clinical 

improvement requirement: 

• The totality of the circumstances is 

considered when making a 

determination that a new medical 

service or technology represents an 

advance that substantially improves, 

relative to services or technologies 

previously available, the diagnosis or 

treatment of Medicare beneficiaries. 

• A determination that a new medical 

service or technology represents an 

advance that substantially improves, 

relative to services or technologies 

previously available, the diagnosis or 

treatment of Medicare beneficiaries 

means— 

++ The new medical service or 

technology offers a treatment option for 

a patient population unresponsive to, or 

ineligible for, currently available 

treatments; 

++ The new medical service or 

technology offers the ability to diagnose 

a medical condition in a patient 

population where that medical 

condition is currently undetectable or 

offers the ability to diagnose a medical 

condition earlier in a patient population 

than allowed by currently available 

methods, and there must also be 

evidence that use of the new medical 

service or technology to make a 

diagnosis affects the management of the 

patient; or 

++ The use of the new medical service 

or technology significantly improves 

clinical outcomes relative to services or 

technologies previously available as 

demonstrated by one or more of the 

following: 

—A reduction in at least one clinically 

significant adverse event, including a 

reduction in mortality or a clinically 

significant complication. 

—A decreased rate of at least one 

subsequent diagnostic or therapeutic 

intervention (for example, due to 

reduced rate of recurrence of the 

disease process). 

—A decreased number of future 

hospitalizations or physician visits. 

—A more rapid beneficial resolution of 

the disease process treatment 

including, but not limited to, a 

reduced length of stay or recovery 

time; an improvement in one or more 

activities of daily living; an improved 

quality of life; or a demonstrated 

greater medication adherence or 

compliance. 

++ The totality of the circumstances 

otherwise demonstrates that the new 

medical service or technology 

substantially improves, relative to 

technologies previously available, the 

diagnosis or treatment of Medicare 

beneficiaries. 

• Evidence from the following 

published or unpublished information 

sources from within the United States or 

elsewhere may be sufficient to establish 

that a new medical service or 

technology represents an advance that 

substantially improves, relative to 

services or technologies previously 

available, the diagnosis or treatment of 

Medicare beneficiaries: Clinical trials, 

peer reviewed journal articles; study 

results; meta-analyses; consensus 

statements; white papers; patient 

surveys; case studies; reports; 

systematic literature reviews; letters 

from major healthcare associations; 

editorials and letters to the editor; and 

public comments. Other appropriate 

information sources may be considered. 

• The medical condition diagnosed or 

treated by the new medical service or 

technology may have a low prevalence 

among Medicare beneficiaries. 

• The new medical service or 

technology may represent an advance 

that substantially improves, relative to 

services or technologies previously 

available, the diagnosis or treatment of 

a subpopulation of patients with the 

medical condition diagnosed or treated 

by the new medical service or 

technology. 

Section 1886(d)(5)(K)(viii) of the Act 

requires that as part of the process for 

evaluating new medical services and 

technology applications, the Secretary 

shall do the following: 

• Provide for public input regarding 

whether a new service or technology 

represents an advance in medical 

technology that substantially improves 

the diagnosis or treatment of Medicare 

beneficiaries before publication of a 

proposed rule. 

• Make public and periodically 

update a list of all the services and 

technologies for which an application is 

pending. 

• Accept comments, 

recommendations, and data from the 

public regarding whether the service or 

technology represents a substantial 

improvement. 

• Provide for a meeting at which 

organizations representing hospitals, 

physicians, manufacturers, and any 

other interested party may present 

comments, recommendations, and data 

to the clinical staff of CMS as to whether 

the service or technology represents a 

substantial improvement before 

publication of a proposed rule. 


khammond on DSKJM1Z7X2PROD with NOTICES
74964 Federal Register / Vol. 89, No. 178 / Friday, September 13, 2024 / Notices 

The opinions and presentations 

provided during this meeting will assist 

us as we evaluate the new medical 

services and technology applications for 

FY 2026. 

II. New Technology Town Hall Meeting 

Format and Conference Call 

Information 

A. Format of the Town Hall Meeting 

As noted in section I. of this notice, 

we are required to provide for a meeting 

at which organizations representing 

hospitals, physicians, manufacturers, 

and any other interested party may 

present comments, recommendations, 

and data to the clinical staff of CMS 

concerning whether the service or 

technology represents a substantial 

clinical improvement. This meeting will 

allow for a discussion of the substantial 

clinical improvement criterion for the 

FY 2026 applications for new 

technology add-on payments. 

Information regarding the applications 

can be found on our website at http:// 

www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatient

PPS/newtech.html. 

The majority of the meeting will be 

reserved for presentations of comments, 

recommendations, and data from 

registered presenters. The time for each 

presentation will be approximately 10 

minutes, with additional time reserved 

for questions, and will be based on the 

number of presentations. Individuals 

who would like to present must register 

and submit their agenda item(s) via 

email to newtech@cms.hhs.gov by the 

dates specified in the DATES section of 

this notice. 

Depending on the number of 

presentations, we will determine if a 

second meeting day is necessary. The 

final schedule for the New Technology 

Town Hall meeting will be posted on 

the CMS website at http://www.cms.gov/ 

Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/ 

newtech.html by November 25, 2024 to 

inform the public of the number of days 

of the meeting. 

In addition, written comments will 

also be accepted and presented at the 

meeting if they are received via email to 

newtech@cms.hhs.gov by the date 

specified in the DATES section of this 

notice. Written comments may also be 

submitted after the meeting for our 

consideration. If the comments are to be 

considered before the publication of the 

FY 2026 IPPS/LTCH PPS proposed rule, 

the comments must be received via 

email to newtech@cms.hhs.gov by the 

date specified in the DATES section of 

this notice. 

B. Conference Call and Webinar 

Information 

As noted previously, the New 

Technology Town Hall meeting will be 

held virtually. There will be an option 

to participate in the New Technology 

Town Hall Meeting via webinar and a 

toll-free teleconference phone line. 

Information on the option to participate 

via webinar and a teleconference dial-in 

will be provided through an upcoming 

listserv/email notice to registrants and 

will appear on the final meeting agenda, 

which will be posted on the New 

Technology website at: http://

www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatient

PPS/newtech.html. Continue to check 

the website for updates. 

C. Disclaimer 

We cannot guarantee reliability for a 

webinar. 

III. Registration Instructions 

The Division of New Technology in 

CMS is coordinating the meeting 

registration for the New Technology 

Town Hall meeting on substantial 

clinical improvement. While there is no 

registration fee, individuals planning to 

present at the New Technology Town 

Hall meeting must register to present. 

Registration for presenters may be 

completed by sending an email to 

newtech@cms.hhs.gov, by the date 

specified in the DATES section of this 

notice. Please include the name and 

email address of the presenter(s), as well 

as address, telephone number, and the 

name of the technology for which they 

will be presenting. 

Registration for attendees not 

presenting at the meeting is not 

required. 

IV. Collection of Information 

This document does not impose 

information collection requirements, 

that is, reporting, recordkeeping, or 

third-party disclosure requirements. 

Consequently, there is no need for 

review by the Office of Management and 

Budget under the authority of the 

Paperwork Reduction Act of 1995 (44 

U.S.C. chapter 35). 

The Administrator of the Centers for 

Medicare & Medicaid Services (CMS), 

Chiquita Brooks-LaSure, having 

reviewed and approved this document, 

authorizes Chyana Woodyard, who is 

the Federal Register Liaison, to 

electronically sign this document for 

purposes of publication in the Federal 

Register. 

Chyana Woodyard, 

Federal Register Liaison, Centers for Medicare 

& Medicaid Services. 

[FR Doc. 2024–20791 Filed 9–12–24; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

[Assistance Listing Number: 93.652] 

Announcement of the Intent To Award 

a Within Scope Awarding AgencyInitiated Non-Competitive Supplement 

With Extension to the American Public 

Human Services Association for the 

Association of Administrators of the 

Interstate Compact on the Placement 

of Children (AAICPC) in Washington, 

DC 

AGENCY: Children’s Bureau (CB), 

Administration for Children and 

Families (ACF), Department of Health 

and Human Services (HHS). 

ACTION: Notice of Issuance of a within 

scope awarding agency-initiated noncompetitive supplement with extension. 

SUMMARY: The ACF, ACYF, CB, Division 

of Capacity Building announces the 

intent to award a within scope awarding 

agency-initiated non-competitive 

supplement with extension in the 

amount of up to $1,600,000, to the 

American Public Human Services 

Association for its affiliate the 

Association of Administrators of the 

Interstate Compact on the Placement of 

Children (AAICPC) in Washington, DC, 

for the further implementation and 

support nationally of the National 

Electronic Interstate Compact Enterprise 

(NEICE) system. The NEICE is an interjurisdictional electronic system to 

improve administrative efficiency in 

implementing the Interstate Compact on 

the Placement of Children (ICPC), a 

process that ensures safe and suitable 

interstate placements for children in 

foster care. 

DATES: The proposed period of 

performance is September 30, 2024, 

through September 29, 2025. 

FOR FURTHER INFORMATION CONTACT: June 

Dorn, National Adoption Specialist, 

Children’s Bureau, Division of Capacity 

Building, 330 C St. SW, Suite 3521B, 

Washington, DC 20201. Telephone: 

(202) 205–9240; Email: June.Dorn@

acf.hhs.gov. 

SUPPLEMENTARY INFORMATION: Award 

funds will support the continued 


khammond on DSKJM1Z7X2PROD with NOTICES